Bausch Health Companies Inc. (BHC) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with increased revenue and reduced debt, alongside optimistic guidance. The company's strategic initiatives, including acquisitions and product launches, are promising. Despite some management vagueness in the Q&A, the overall sentiment is positive, particularly with raised guidance and solid growth in key segments like Xifaxan and Solta. Given the company's market cap, these factors suggest a positive stock price movement in the short term.
Key Financial Performance
Revenue (Q4 2025) $2.796 billion, up 9% year-over-year. Growth attributed to strong operational performance across all metrics.
Adjusted Gross Margin (Q4 2025) 71.6%, down 80 basis points year-over-year. Decline due to unspecified factors.
Adjusted Operating Expenses (Q4 2025) $1.33 billion, an increase of $75 million year-over-year. Increase attributed to higher spending to support growth.
Adjusted R&D Expenses (Q4 2025) $161 million, a $2 million decrease year-over-year. Reduction due to unspecified factors.
Adjusted EBITDA (Q4 2025) $1.52 billion, up 13% year-over-year. Growth driven by efficient operations and thoughtful spending management.
Adjusted Operating Cash Flow (Q4 2025) $515 million. No year-over-year comparison provided.
Revenue (Full Year 2025) 7% growth year-over-year on a reported basis. Growth attributed to broad-based performance across the enterprise.
Adjusted EBITDA (Full Year 2025) Double-digit growth year-over-year, excluding Bausch + Lomb. Growth driven by operational efficiencies and strong commercial performance.
Salix Revenue (Q4 2025) $693 million, up 9% year-over-year. Growth driven by double-digit script growth and higher-than-expected residual volume from Medicaid customers.
International Segment Revenue (Q4 2025) $306 million, up 10% year-over-year on a reported basis and 2% on an organic basis. Growth driven by strong performance in EMEA and LatAm, partially offset by a 6% contraction in Canada.
Solta Medical Revenue (Q4 2025) $137 million, down 1% year-over-year on a reported basis and flat on an organic basis. Decline attributed to the transition of a full-service distributor in China.
Diversified Segment Revenue (Q4 2025) $255 million, up 12% year-over-year. Growth driven by improved net pricing.
Bausch + Lomb Revenue (Q4 2025) $1.405 billion, up 10% year-over-year. Growth led by a 16% increase in the pharmaceuticals business and 8% growth in Vision Care and Surgical businesses.
Net Debt Reduction (Q4 2025) Reduced by $320 million. Reduction attributed to strong cash flow generation.
Xifaxan Revenue (Full Year 2025) 11% growth year-over-year. Growth attributed to strong commercial team efforts.
Thermage Revenue (Full Year 2025) 19% growth year-over-year. Growth driven by strong performance in Asia Pacific.
CABTREO and Ryaltris Revenue (Full Year 2025) Double-digit growth year-over-year. Growth attributed to consistent demand and targeted investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Xifaxan revenue: Grew 11% for the year, reflecting the continued impact of the commercial team's efforts.
Thermage revenue: Grew a robust 19%, anchored in Asia Pacific.
Ryaltris and CABTREO: Also grew very well, reflecting consistent demand, strong field activity, and targeted investments.
Acquisition of Shibo: Acquired Shibo, a full-service aesthetics distribution platform in China, strengthening direct commercial presence in this key market.
International segment growth: EMEA and LatAm grew double digits on a reported basis, while Canada contracted 6%.
Solta in South Korea: Reported revenue in South Korea was up 40%, making it the largest revenue-generating geography for Solta in 2025.
Revenue growth: Bausch Health (excluding Bausch + Lomb) increased revenue by 9% on a reported basis and 5% on an organic basis in Q4 2025.
Adjusted EBITDA: Increased by approximately 9% compared to the prior year period.
Debt maturity profile: Improved by approximately $1.7 billion through a debt exchange in late December 2025.
Business development: Proactively pursuing business development to enhance long-term outlook.
AI in Salix: Leveraging AI for faster, smarter, and more efficient patient targeting and treatment acceleration.
Expansion in cardiometabolic market: Entered the cardiometabolic market in Latin America, representing a large and growing opportunity.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
RED-C Phase III trial results: The Phase III trial for RED-C did not meet its primary endpoint, raising concerns about the viability of this program and potential setbacks in R&D investments.
Solta Medical segment performance in China: The transition of the full-service distributor in China negatively impacted Solta's revenue in Q4, highlighting risks associated with distributor transitions and market-specific challenges.
Canada revenue contraction: Canada's revenue declined by 6% due to increased generic competition for Wellbutrin, indicating challenges in maintaining market share for certain products.
Debt maturity profile: Although the company improved its debt maturity profile, the high level of debt and reliance on refinancing transactions pose ongoing financial risks.
Timing of cash interest payments: The change in timing of cash interest payments following refinancing led to a significant year-over-year decline in adjusted operating cash flow for Q4, which could impact liquidity management.
Nonrecurring revenue drivers: Some of the 2025 growth was attributed to nonrecurring revenue drivers, which may not sustain future growth rates.
Generic competition in Canada: Increased generic competition for Wellbutrin in Canada highlights the risk of revenue erosion in markets with high generic penetration.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Guidance: Expected revenues to be between $5.25 billion and $5.4 billion, representing a 3% increase year-over-year at the midpoint.
2026 Adjusted EBITDA Guidance: Expected to be between $2.875 billion and $2.950 billion, representing a 4% increase year-over-year at the midpoint.
2026 Adjusted Operating Cash Flow Guidance: Expected to be between $1.2 billion and $1.275 billion, representing a 4% increase year-over-year at the midpoint.
2026 Revenue Phasing: Anticipates a stronger growth rate in the first half of 2026 due to temporary benefits recorded in the second half of 2025.
Salix Segment Outlook for 2026: Plans to leverage customer insights and AI for patient targeting and direct-to-consumer advertising. Focus on advancing the Phase III program for Larsucosterol in alcohol-associated hepatitis.
Solta Segment Outlook for 2026: Expects double-digit growth supported by the acquisition of Shibo's aesthetics business in China, investments in R&D, and manufacturing capacity expansion.
International Segment Outlook for 2026: Anticipates growth driven by strong performance in EMEA, Latin America, and Canada. Plans to expand in the cardiometabolic market in Latin America and leverage strong brand positions in dermatology and promoted products.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Post RED-C readout, what is your updated decision framework for the separation? How are you thinking about gating items and debt repayments?
A:There is no change in the decision framework. The company remains focused on repaying debt and reinvesting in the business, including promoting existing products, developing new products, and accelerating business development activities after refinancing.
Q:Can you provide more color about your business development plans?
A:The company is focusing on acquiring assets that align with its therapeutic areas and leveraging its commercial team. Recent acquisitions include DURECT for its platform potential and Shibo for Solta. The company is also exploring other acquisition opportunities to enhance its portfolio.
Q:Can you share some details about the Shibo integration and its impact on Solta's revenue and EBITDA growth?
A:The Shibo integration has been smooth, with strong collaboration between teams. The acquisition closed on December 1, 2025. There was a $10-15 million EBITDA impact in the quarter due to accounting adjustments and a temporary halt in sales in November.
Q:Should we expect generics of Aplenzin and BRYHALI launching this year? What is the expected revenue erosion?
A:Generics of Aplenzin are expected to launch in June, with a standard erosion curve anticipated. The company does not expect unusual behavior in revenue erosion.
Q:Can you share details about the Phase III study design for Larsucosterol?
A:The Phase III study is a U.S.-only trial with 350 patients randomized between drug and placebo. The primary endpoint is 90-day transplant-free survival. The study design reflects Phase II results, which showed over 50% reduction in 90-day mortality. The company believes replicating this result would be significant.
Q:Is 2026 expected to be the peak year for Xifaxan sales? What are the plans to mitigate the impact of renegotiated Medicare rates in 2027?
A:2025 might be the peak year for Xifaxan due to one-time benefits. The company plans to continue growing sales in existing channels and leveraging its AI engine to drive efficiency. There is still unmet need in the market, with only 40-50% of diagnosed patients being treated.
Q:What is the framework for the full separation of Bausch + Lomb?
A:The company is waiting for the market to reflect the value of Bausch + Lomb. The refinancing provides flexibility until 2028, allowing patience in monetizing the equity stake. The most likely outcome is selling down the equity stake rather than distributing shares.
Q:What is the EBITDA impact expected in 2027 due to IRA pricing changes and Xifaxan LOE?
A:The average EBITDA for 2026 and 2027 is expected to be similar to 2025. There will be a dip in 2027, with an estimated EBITDA of around $2.7 billion.
Q:What is the outlook for Xifaxan generics and the company's confidence in retaining exclusivity until 2028?
A:The company expects a generic in January 2028. Teva remains the first filer, and there are ongoing court cases. The company will provide updates as the legal process progresses.
Q:What is the scope of business development given the current capital structure?
A:The company is open to various types and sizes of deals, focusing on maximizing portfolio value and leveraging its commercial capabilities. Recent acquisitions include DURECT and Shibo.
Q:What was the impact of higher-than-planned residual volume from state Medicaid in Q4?
A:The impact was less than $50 million in revenue, primarily associated with Xifaxan.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the expected margin accretion from the Shibo integration, the exact revenue erosion for BRYHALI generics, and the precise framework for the full separation of Bausch + Lomb. Additionally, responses about the scope of business development and the monetization strategy for Bausch + Lomb equity stake were somewhat vague.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Administrators discussion
BL pharmaceutical
CABTREO
EMEA LatAm
Full Conference
Head
Health Full
Lomb Page
Medicaid
Medical
Officer Chief
Page basis
Page revenue
President Investor
Relations today
Revenues increase
Sarafian Vice
Vice President
ability
access
aesthetic
basis period
debt exchange
debt maturity
driver
excellence
flexibility
flow debt
improvement
maturity profile
month
opportunity progress
priority approach
rate
refinancing
result JJ
service
slide presentation
team
transaction
year debt
BHC Transcript
Bausch Health Companies Inc. (BHC) Q4 2025 Earnings Call Transcript
Positive2-18
The earnings call highlights strong financial performance with increased revenue and reduced debt, alongside optimistic guidance. The company's strategic initiatives, including acquisitions and product launches, are promising. Despite some management vagueness in the Q&A, the overall sentiment is positive, particularly with raised guidance and solid growth in key segments like Xifaxan and Solta. Given the company's market cap, these factors suggest a positive stock price movement in the short term.
Bausch Health Companies Inc. (BHC) Presents at Evercore 8th Annual Healthcare Conference Transcript
Neutral12-2
Bausch Health Companies Inc. (BHC) Q3 2025 Earnings Call Transcript
Positive10-29
The earnings call indicates strong growth in Bausch + Lomb and international segments, and strategic initiatives like debt refinancing and acquisitions bolster long-term prospects. Despite some revenue declines and conservative guidance adjustments, positive Q&A insights on Xifaxan's growth and RED-C trials suggest optimism. Market reaction should be positive, with a projected 2-8% stock price increase, considering the company's market cap and strategic positioning.
Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript
Positive7-30
The earnings call presents a mix of positive and neutral factors. Strong financial performance, including revenue and EBITDA growth, and positive developments in product segments like Salix and Solta Medical, contribute to a positive outlook. However, concerns over the IRA impact on Xifaxan and limited details on the DURECT acquisition introduce some uncertainty. The shift away from share buybacks could be seen as a negative, but overall, the positive financial metrics and strategic focus on growth suggest a positive stock movement in the short term.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
